< Back to previous page

Project

The SERENA study: Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes: a double blind RCT (SERENA)

The incidence of gestational diabetes (GDM) is rising with prevalence rates around 9-12% in Flanders.
GDM is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who
will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention
after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, we aim therefore to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in
women with a recent history of GDM and glucose intolerance in early postpartum. Semaglutide is currently the strongest once-weekly GLP-1agonist available with greatest potential to reduce the risk
to develop T2DM and the long-term cardiovascular risk. Prevention of T2DM and early diagnosis of T2DM before the development of complications, has been shown to be cost-effective. Prevention of
T2DM in this high-risk population, has therefore a high potential for important cost savings for the Flemish and Belgium health care system.

Date:1 Oct 2022 →  Today
Keywords:gestational diabetes (GDM), type 2 diabetes (T2DM), GLP-1 agonist semaglutide
Disciplines:Endocrinology and metabolic diseases not elsewhere classified